Evive Biotech meets primary and secondary endpoints in global ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SHANGHAI, July 8, 2020 /PRNewswire-AsiaNet/-- --Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF --Key milestone and validation for Evive's novel biologic development capability and technology platform --Key comp...
Authors: LATEST ASIANET NEWS RELEASES